Alexa Fluor^® 647 Mouse Anti-Human GPR183 (EBI2) Antibody (S-3016)

GPR183 (also designated Epstein–Barr virus-induced gene 2, EBI2) is a seven-transmembrane Gαi-coupled GPCR discovered through its strong up-regulation in Epstein–Barr virus–infected Burkitt lymphoma cells; it is expressed on B cells, T cells, dendritic cells and other immune and non-immune cells, binds the oxysterol 7α,25-dihydroxycholesterol (7α,25-OHC) as its most potent endogenous ligand, and drives chemotaxis and positioning of B and T cells within secondary lymphoid organs by sensing oxysterol gradients generated by the enzymes CH25H and CYP7B1; downstream signalling involves calcium mobilisation, ERK1/2 and p38 MAPK activation, β-arrestin recruitment and SRE-mediated transcription, thereby orchestrating adaptive immune responses, while genetic or pharmacologic interference with the GPR183/7α,25-OHC axis leads to impaired antibody production, defective plasma-cell localisation and altered trafficking of innate lymphoid cells, and has implicated the receptor in autoimmune, inflammatory and viral diseases, making GPR183 and its ligand attractive therapeutic targets.